Efficacy of poziotinib in HER2 exon 20 insertion NSCLC patients who received prior platinum-based and HER2 targeted therapies

被引：0
|
作者：
Prelaj, A. [1 ]
Le, X. [2 ]
Proto, C. [3 ]
Baik, C. S. [4 ]
Tchekmedyian, N. [5 ]
Heymach, J. [6 ]
Bhat, G. [7 ]
Cornelissen, R. [8 ]
机构：
[1] Fdn IRCCS Ist Nazl Tumori, Oncol Med Torac Dept, Milan, Italy
[2] Univ Texas MD Anderson Canc Ctr, Thorac Head & Neck, Houston, TX USA
[3] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy
[4] Univ Washington, Dept Med Oncol, Seattle Canc Care Alliance, Seattle, WA USA
[5] City Hope Natl Med Ctr, Med Oncol, Comprehens Canc Ctr, Duarte, CA USA
[6] MD Anderson Canc Ctr, Thorac Oncol, Houston, TX USA
[7] Spectrum Pharmaceut, Dept Clin Sci, Irvine, CA USA
[8] Erasmus MC Univ, Pulm Med, Med Ctr, Rotterdam, Netherlands
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2422
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1389P
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Estimating scenarios for survival time in patients with HER2 positive, metastatic breast cancer starting HER2 targeted therapies
    Vasista, A.
    Stockler, M.
    West, T.
    Wilcken, N.
    Kiely, B.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S216 - S216
  • [32] Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC
    Baraibar, Iosune
    Mezquita, Laura
    Gil-Bazo, Ignacio
    Planchard, David
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2020, 148
  • [33] A Phase I Trial of the HER2 Exon 20 Inhibitor, BI 1810631, In Patients With Advanced Solid Tumors With HER2 Aberrations
    Opdam, F.
    Heymach, J.
    Barve, M.
    Gibson, N.
    Sadrolhefazi, B.
    Serra, J.
    Yamamoto, N.
    Yoh, K.
    Wu, Y. -L.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S421 - S422
  • [34] ESTIMATING SCENARIOS FOR SURVIVAL TIME IN PATIENTS WITH HER2 POSITIVE, METASTATIC BREAST CANCER (MBC) STARTING HER2 TARGETED THERAPIES
    Vasista, A.
    Stockler, M.
    West, T.
    Wilcken, N.
    Kiely, B.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2015, 11 : 44 - 45
  • [35] Poziotinib overcomes de novo resistance of HER2 exon 20 mutations in NSCLC and other cancers: Preclinical studies and initial clinical testing
    Robichaux, Jacqulyne P.
    Elamin, Yasir Y.
    Tan, Zhi
    Negrao, Marelo Vailati
    Routbort, Mark
    Roeck, Brent
    Li, Shuai
    Liu, Shengwu
    Chen, Ting
    Ahnert, Jordi Rodon
    Diao, Lixia
    Nilsson, Monique B.
    Zhang, Shuxing
    Yang, Zane
    Wang, Jing
    Meric-Bernstam, Funda
    Wong, Kwok-Kin
    Heymach, John V.
    CANCER RESEARCH, 2018, 78 (13)
  • [36] Anti-angiogenic Therapy or Immunotherapy? A Multicenter Study of Patients with Advanced NSCLC with EGFR / HER2 exon 20 Insertion Mutations
    Chu, T.
    Li, J.
    Xie, M.
    Zhao, R.
    Qiang, H.
    Chang, Q.
    Qian, J.
    Lu, H.
    Shen, Y.
    Han, Y.
    Su, C.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S628 - S628
  • [37] Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling
    Birgit Wilding
    Dirk Scharn
    Dietrich Böse
    Anke Baum
    Valeria Santoro
    Paolo Chetta
    Renate Schnitzer
    Dana A. Botesteanu
    Christoph Reiser
    Stefan Kornigg
    Petr Knesl
    Alexandra Hörmann
    Anna Köferle
    Maja Corcokovic
    Simone Lieb
    Guido Scholz
    Jens Bruchhaus
    Markus Spina
    Josef Balla
    Biljana Peric-Simov
    Jasmin Zimmer
    Sophie Mitzner
    Thomas N. Fett
    Alexandra Beran
    Lyne Lamarre
    Thomas Gerstberger
    Daniel Gerlach
    Markus Bauer
    Andreas Bergner
    Andreas Schlattl
    Gerd Bader
    Matthias Treu
    Harald Engelhardt
    Stephan Zahn
    Julian E. Fuchs
    Johannes Zuber
    Peter Ettmayer
    Mark Pearson
    Mark Petronczki
    Norbert Kraut
    Darryl B. McConnell
    Flavio Solca
    Ralph A. Neumüller
    Nature Cancer, 2022, 3 : 821 - 836
  • [38] Identifying efficacy of targeted HER2 antibodies in sensitization of HER2 positive breast cancer to fractionated radiation
    Song, Patrick N.
    Lu, Yun
    Napier, Tiara
    Samuel, Sharon
    Heinzman, Katherine
    Lapi, Suzanne E.
    Sorace, Anna G.
    CANCER RESEARCH, 2021, 81 (04)
  • [39] Weakly supervised bilayer convolutional network in segmentation of HER2 related cells to guide HER2 targeted therapies
    Wang, Ching-Wei
    Lin, Kun-Lin
    Muzakky, Hikam
    Lin, Yi-Jia
    Chao, Tai-Kuang
    COMPUTERIZED MEDICAL IMAGING AND GRAPHICS, 2023, 108
  • [40] Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling
    Wilding, Birgit
    Scharn, Dirk
    Boese, Dietrich
    Baum, Anke
    Santoro, Valeria
    Chetta, Paolo
    Schnitzer, Renate
    Botesteanu, Dana A.
    Reiser, Christoph
    Kornigg, Stefan
    Knesl, Petr
    Hoermann, Alexandra
    Koeferle, Anna
    Corcokovic, Maja
    Lieb, Simone
    Scholz, Guido
    Bruchhaus, Jens
    Spina, Markus
    Balla, Josef
    Peric-Simov, Biljana
    Zimmer, Jasmin
    Mitzner, Sophie
    Fett, Thomas N.
    Beran, Alexandra
    Lamarre, Lyne
    Gerstberger, Thomas
    Gerlach, Daniel
    Bauer, Markus
    Bergner, Andreas
    Schlattl, Andreas
    Bader, Gerd
    Treu, Matthias
    Engelhardt, Harald
    Zahn, Stephan
    Fuchs, Julian E.
    Zuber, Johannes
    Ettmayer, Peter
    Pearson, Mark
    Petronczki, Mark
    Kraut, Norbert
    McConnell, Darryl B.
    Solca, Flavio
    Neumuller, Ralph A.
    NATURE CANCER, 2022, 3 (07) : 821 - +
12345